Open access
Jul 2026
Integrated Patient-Derived Xenograft and Patient-Derived Cell Models Reveal Therapeutic Vulnerabilities Beyond Standard-of-Care Therapy in Endometrial Cancer
A comprehensive PDX and PDC platform is established as a robust translational resource for preclinical drug evaluation of endometrial cancer and identifies clinically actionable therapeutic advantages, including an epigenetic combination regimen.
Tian-Yue Li, Fang Huang, Xiaohao Huang et al.
· bioRxiv · 0 citations